Author Interviews, Brigham & Women's - Harvard, Infections, JAMA, Multiple Sclerosis, Neurological Disorders / 19.03.2024

MedicalResearch.com Interview with: Marianna Cortese, MD, PhD Senior Research ScientistDepartment of Nutrition Harvard T.H. Chan School of Public HealthBoston, MA 02115   MedicalResearch.com: What is the background for this study? Response: In a study published in Science in 2022, we reported compelling evidence that infection with the Epstein-Barr virus is the leading cause of Multiple Sclerosis. This is a follow-up study to investigate more in depth whether the antibody response to EBV is distinct in individuals with MS compared to individuals without MS and whether there is a part of EBV that the immune response is particularly targeting. For this purpose we assessed the immune response to all protein parts (peptides) of EBV and their association with MS. Previous studies could only look at parts of EBV and this is the first study looking at all EBV peptides. Antibodies to EBV (especially to a protein called EBNA1) are known to be overall higher in individuals with MS, so we also tested whether immune response overall or the immune response to specific EBV protein parts was more important. If the immune response to a specific EBV protein part (peptide) would be standing out or distinguishing individuals with MS, we hypothesized, it could point to a specific mechanism of how EBV may cause MS, i.e. it could point for example towards “molecular mimicry”, which is when antibodies targeting a pathogen start targeting a body-own structure (for example in the brain) which resembles the protein parts of the pathogen. (more…)
Author Interviews, Genetic Research, Infections, Neurological Disorders / 14.12.2022

MedicalResearch.com Interview with: Dr. Eli Hatchwell, MA MB BChir (Cantab) DPhil (Oxon) BA (OU) Chief Scientific Officer Population Bio UK, Inc. Begbroke Science Park Begbroke Hill Begbroke, Oxfordshire United Kingdom MedicalResearch.com: What is the background for this study? Response: Progressive Multifocal Leukoencephalopathy (PML) is a devastating condition that is associated with a number of clinical situations, including treatment with a variety of drugs. Of these, the best known is natalizumab (Tysabri), which is a very successful drug in the treatment of MS (multiple sclerosis). Only a small proportion of patients treated with natalizumab develop PML and this has always been a mystery. The study was based on a hypothesis that some individuals have an underlying susceptibility to developing PML, based on the presence of variants in genes that are important in the immune system. The study identified several of these variants. (more…)
Author Interviews, Multiple Sclerosis / 19.01.2022

MedicalResearch.com Interview with: Marcus Koch MD PhD Associate Professor of Neurology Multiple Sclerosis Program University of Calgary MedicalResearch.com: What is the background for this study? Response: Primary progressive multiple sclerosis (PPMS) is the least common, but also the least treatable form of multiple sclerosis. PPMS does not react well to commonly used MS treatments. We believe that this is at least in part because PPMS is driven by other disease mechanisms. One disease mechanism that we believe is important in PPMS is microglial activation. Microglial cells are a type of cell in the brain and spinal cord that normally have beneficial functions, such as clearing debris or assisting repair after injury. In PPMS however, microglial cells are chronically active, and we believe that this chronic microglial activation contributes to tissue damage. (more…)